SCHEDULE 13G: BlackRock Discloses 5.1% Stake in Aclaris Therapeutics
Beneficial Ownership Report
BlackRock, Inc. has reported a 5.1% beneficial ownership stake in Aclaris Therapeutics, Inc., holding 5,471,711 shares of common stock as of June 30, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 5,471,711 shares of Aclaris Therapeutics, Inc. common stock.
- This represents 5.1% of the total outstanding common stock of Aclaris Therapeutics, Inc.
- BlackRock holds sole voting power over 5,331,423 shares and sole dispositive power over 5,471,711 shares.
- The filing was made by BlackRock, Inc. as a parent holding company, with its principal business office located at 50 Hudson Yards, New York, NY 10001.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- Subsidiaries identified as potentially owning 5% or greater of the outstanding shares include BlackRock Advisors, LLC, BlackRock (Netherlands) B.V., BlackRock Fund Advisors, BlackRock Institutional Trust Company, National Association, BlackRock Financial Management, Inc., and BlackRock Investment Management, LLC.
Sentiment
Score: 7
Explanation: The disclosure of a significant stake by a major institutional investor like BlackRock is generally viewed positively or neutrally, as it indicates confidence in the company, even if the investment is passive.
Positives
- BlackRock, a major institutional investor, holding a significant stake (5.1%) can be seen as a vote of confidence in Aclaris Therapeutics, Inc.
- The investment is stated to be for ordinary course of business, indicating a passive investment rather than an activist intent, which can provide stability.
Future Outlook
NA
Industry Context
Schedule 13G filings are mandatory disclosures by institutional investors who acquire more than 5% of a company's voting stock, indicating a significant, typically passive, investment. BlackRock's disclosure of a 5.1% stake in Aclaris Therapeutics, Inc. signals its position as a notable shareholder in the biotechnology and pharmaceutical sector, aligning with its strategy of diversified portfolio management across various industries.
Stakeholder Impact
- Shareholders may view BlackRock's significant stake as a positive signal, potentially increasing investor confidence and liquidity for Aclaris Therapeutics, Inc. common stock.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney date, which was revoked by the new one. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 2025-06-30 | Date of event which requires filing of this statement (reporting period end date). |
| 2025-07-17 | Filing date of the Schedule 13G statement. |
Keywords
Aclaris Therapeutics, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Pharmaceuticals, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.